Last reviewed · How we verify
Thymosin alpha1 & Pegylated Interferon-alpha2a
This combination enhances immune response by stimulating T-cell maturation and proliferation (thymosin alpha1) while amplifying interferon-mediated antiviral and anti-tumor effects (pegylated interferon-alpha2a).
This combination enhances immune response by stimulating T-cell maturation and proliferation (thymosin alpha1) while amplifying interferon-mediated antiviral and anti-tumor effects (pegylated interferon-alpha2a). Used for Chronic hepatitis B (marketed combination therapy), Chronic hepatitis C (marketed combination therapy).
At a glance
| Generic name | Thymosin alpha1 & Pegylated Interferon-alpha2a |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Immunomodulator combination |
| Target | T-cell maturation pathway; interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Oncology, Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Thymosin alpha1 is an immunomodulatory peptide that promotes T-cell development and activation, particularly enhancing CD4+ and CD8+ T-cell function. Pegylated interferon-alpha2a is a type I interferon with extended half-life that activates natural killer cells, macrophages, and promotes antiviral/anti-tumor gene expression. Together, they provide synergistic immune stimulation for treating chronic viral infections and certain malignancies.
Approved indications
- Chronic hepatitis B (marketed combination therapy)
- Chronic hepatitis C (marketed combination therapy)
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Injection site reactions
Key clinical trials
- Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients (PHASE1, PHASE2)
- Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B (PHASE4)
- Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin. (PHASE3)
- Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin (PHASE3)
- Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: